Related Experiment Videos
Development of an injectable formulation for the novel lipid A analog E5531 using a 'pH-jump method'
1Formulation Research Laboratory, Kawashima, Eisai Co., Ltd., Gifu 510-6195, Japan
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan
|December 4, 2004
Summary
A novel pH-jump method created injectable E5531 nanoparticles for septic shock treatment. Particle properties, like membrane fluidity, influenced drug pharmacokinetics in rats.
Area of Science:
- Pharmaceutical Sciences
- Drug Delivery Systems
- Nanotechnology
Background:
- Septic shock treatment requires effective injectable drug formulations.
- E5531, a synthetic lipid A analog, shows potential for treating septic shock.
- Developing stable, injectable nanoparticle formulations is crucial for drug efficacy.
Purpose of the Study:
- To develop an injectable nanoparticle formulation of E5531 using a pH-jump method.
- To characterize the physicochemical properties of the E5531 nanoparticles.
- To investigate the relationship between particle properties and in vivo pharmacokinetics.
Main Methods:
- A pH-jump method involving alkaline dispersion (pH 11.0, 50°C) followed by neutralization to pH 7.3.
- Characterization of nanoparticle size (approx. 20 nm) and vesicular structure.
- Sterilization, aseptic filling, lyophilization, and pharmacokinetic studies in rats.
Main Results:
- The pH-jump method successfully produced stable, vesicular E5531 nanoparticles (approx. 20 nm).
- Nanoparticle size remained consistent before and after lyophilization.
- Membrane fluidity was influenced by dispersal conditions and Ca(2+) addition, correlating with pharmacokinetic profiles in rats.
Conclusions:
- The developed pH-jump method is suitable for creating injectable E5531 nanoparticle formulations.
- Physicochemical properties, particularly membrane fluidity, are critical determinants of E5531 pharmacokinetics.
- This formulation approach holds promise for the therapeutic application of E5531 in septic shock.